← Back to Clinical Trials
Recruiting NCT06255730

The Effect of Stellate Ganglion Block on Insomnia Patients

Trial Parameters

Condition Insomnia
Sponsor Zeng Changhao
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-02-28
Completion 2024-06
Interventions
Stellate Ganglion BlockLidocaine Hydrochloride

Brief Summary

A prospective study was conducted on Insomnia Patients. All the patients were provided with Stellate Ganglion Block. The quality of sleep was evaluated to see if Stellate Ganglion Block can improve Insomnia.

Eligibility Criteria

Inclusion Criteria: * Insomnia patients with the ages over 18. * Meeting the diagnostic criteria for chronic insomnia as per the International Classification of Sleep Disorders (ICSD) or the Diagnostic and Statistical Manual of Mental Disorders (DSM). * Experiencing insomnia symptoms persistently for at least three months. * Not currently using or ceased using medication for insomnia for at least four weeks. * Willing to undergo Stellate Ganglion Block treatment and participate in the study. Exclusion Criteria: * Patients with severe cardiovascular disease, pulmonary disease, or other serious physical health issues. * Pregnant or lactating women. * Patients with mental disorders (such as major depression, anxiety disorders, schizophrenia, etc.) or cognitive impairments. * Patients with known allergies or contraindications to Stellate Ganglion Block treatment. * Patients currently participating in other clinical trials or receiving experimental treatments.

Related Trials